ElbertBurchell: Die Seite wurde neu angelegt: „
GLP-1 and dual GIP/GLP-1 receptor agonists are known to cause delayed gastric emptying, which may increase the risk of residual gastric contents despite preoperative fasting. GLP-1 or dual GIP/GLP-1 receptor agonists. Consider the possibility that patients may have purchased GLP-1 or dual GIP/GLP-1 receptor agonists for aesthetic [http://www.tangjia7.com:8901/estellapritcha MedicGLP Weight Management] loss and may not readily disclose this information…“

2026-08-13T12:34:37Z

Die Seite wurde neu angelegt: „ GLP-1 and dual GIP/GLP-1 receptor agonists are known to cause delayed gastric emptying, which may increase the risk of residual gastric contents despite preoperative fasting. GLP-1 or dual GIP/GLP-1 receptor agonists. Consider the possibility that patients may have purchased GLP-1 or dual GIP/GLP-1 receptor agonists for aesthetic [http://www.tangjia7.com:8901/estellapritcha MedicGLP Weight Management] loss and may not readily disclose this information…“

Neue Seite

GLP-1 and dual GIP/GLP-1 receptor agonists are known to cause delayed gastric emptying, which may increase the risk of residual gastric contents despite preoperative fasting. GLP-1 or dual GIP/GLP-1 receptor agonists. Consider the possibility that patients may have purchased GLP-1 or dual GIP/GLP-1 receptor agonists for aesthetic [http://www.tangjia7.com:8901/estellapritcha MedicGLP Weight Management] loss and may not readily disclose this information unless directly asked. GLP-1 and dual GIP/GLP-1 receptor agonists are a class of medications that are used to treat type II diabetes mellitus and/or obesity. The GLP-1 and dual GIP/GLP-1 receptor agonists available in the UK include dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide. Tirzepatide is a GLP-1 receptor agonist combined with glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Semaglutide is also approved to reduce the risk of cardiovascular events in patients with established cardiovascular [https://sportsrants.com/?s=disease disease]. Some of the GLP-1 and dual GIP/GLP-1 receptor agonists have more than one brand name and more than one indication. Please refer to Annex 1 for the GLP-1 and dual GIP/GLP-1 receptor agonist products currently authorised in the UK with their brand names and indications. Residual gastric content is a risk factor for aspiration in patients who undergo surgery or procedures with general anaesthesia or deep sedation. All GLP-1 and dual GIP/GLP-1 receptor agonists slow down gastric emptying, therefore patients taking these medicines may have a higher risk of pulmonary aspiration due to retained gastric contents. This can potentially lead to severe complications, such as aspiration pneumonia. Cases have been reported in the literature as well as through Yellow Card reports. A recent European review of the available evidence for all GLP-1 and dual GIP/GLP-1 receptor agonists concluded that the data supports an association between GLP-1 or dual GIP/GLP-1 receptor agonists and the potential risk of pulmonary aspiration during anaesthesia or deep sedation because of the delayed gastric emptying associated with these medicines. The findings of this review were considered by the Pharmacovigilance Expert Advisory Committee (PEAG) of the Commission on Human Medicines (CHM), which agreed with the recommendations. The product information of all GLP-1 and dual GIP/GLP-1 receptor agonists has been updated to include the potential risk of pulmonary aspiration under general anaesthesia or deep sedation. The PEAG recommended that the MHRA inform healthcare professionals and patients of the possibility of aspiration in patients using GLP-1 or dual GIP/GLP-1 receptor agonists who undergo surgery or procedures requiring general anaesthesia or deep sedation. The European assessment evaluated whether a specific time to pause the use of a GLP-1 or dual GIP/GLP-1 receptor agonist prior to anaesthesia could be recommended, as well recommending new fasting guidelines or an appropriate medical procedure to confirm an empty stomach. The evidence to support further recommendations was limited and it was concluded that anaesthetists should retain the flexibility to provide individualised assessment. New warnings have been added to the Summaries of Product Characteristics (SmPC) and Patient Information Leaflets. The new advice aims to raise awareness of the risk of pulmonary aspiration amongst healthcare professionals and patients. Anaesthetists are warned that residual gastric contents may remain despite routine recommended fasting in patients taking a GLP-1 or dual GIP/GLP-1 receptor agonists. This should be considered within the preoperative risk assessment, with subsequent management in preventing or minimising the risk. As of 12 December 2024, the MHRA has received a very small number of reports of aspiration during a surgical procedure associated with GLP-1 or dual GIP/GLP-1 receptor agonists, including one case that resulted in aspiration pneumonia. In January 2025, the Association of Anaesthetists published a multidisciplinary consensus statement on ‘Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists (GLP-1). I am pleased to share the news that the UK Good Laboratory Practice Monitoring Authority's (UK GLPMA) guidance on the implementation and maintenance of a risk-based GLP quality assurance (QA) programme has been published. The GLPMA have for some time recognised there was a need to provide guidance to GLP facilities that would allow them to utilise modern quality risk assessment techniques in support of the conduct of GLP studies. This has become particularly apparent for those facilities engaged in activities that require compliance with other quality systems in addition to GLP, such as GMP and GCP. Having a risk-based GLP QA programme should offer facilities the flexibility to focus their resources in areas that present the biggest risk to their compliance status. During the last 13 years of inspecting I have been asked on many occasions how much is enough when it comes to QA. The answer to this question is not necessarily about the number of QA inspections conducted, it is about whether they add value in terms of assuring compliance. Also, are the inspections effective at identifying problems before they have a serious impact on the integrity of the data, compliance of the study or the facility as a whole? What’s right for one facility may not be right for another. The size of the facility, number of staff, amount of GLP work and the other quality systems in place are key factors in determining how much is enough. For [http://pcwang.vip:17608/cedricsexton1 MedicGLP Weight Support] example, the procedures for handling and dealing with deviations, amendments, errors, change etc. These systems can generate a lot of data - what does it tell you and how is it used? The challenge of course is to make sense of the data you have and turn it into meaningful information in order that you can make decisions as to how much QA is enough. Ultimately, the answer is to understand your processes and know where the risks are, then design your QA programme accordingly.

GLP-1 Or Dual GIP/GLP-1 Receptor Agonists - Versionsgeschichte